Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday. A ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $190.00. The company’s shares closed ...

Teva’s Austedo guidance for 2025, at $1.9 billion to $2 billion, currently stands lower than Neurocrine's Ingrezza range. While “both brands are doing quite well,” according to Neurocrine ...

It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...

Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company reported Ingrezza Q4 about 1% below consensus estimates ...

In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Volatile trading persisted on the stock market last week as ...

In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Ten companies were hit hard on Friday as investors digested ...